| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 85.8MM | +28% |
| Operating Income | - | - |
| Operating Expenses | - | - |
| Net Income | 61.5MM | -25% |
| R&D | 2.4MM | -41% |
| G&A | - | - |
| Amortization | 6.5MM | -0% |
| Interest Expense | 6MM | +35% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's largest shareholder. The gross proceeds to be received by the C
Company Sees 35% Year-Over-Year Growth in Q4 Product Revenues
BURLINGAME, Calif., February 29, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted select corporate achievements.
Overview of the Recent Portfolio Addition Renaissance Technologies, led by Jim Simons (Trades, Portfolio), has recently expanded its investment portfolio with the addition of 4,144,447 shares in Innoviva Inc (NASDAQ:INVA). The transaction, which took place on December 29, 2023, reflects a 3.63% increase from the previous holding, marking a significant vote of confidence in the biopharmaceutical company. With a trade price of $16.04 per share, the firm has demonstrated a strategic move to capit...
The great advances and improvements in the treatment of diseases and the effectiveness of these medicines are undoubtedly due to technological progress and how biotech companies take advantage of it for their growth and development. Without the work of these companies, we would still be using very old and ineffective medicines. This new year brings with it very good opportunities to invest in companies in this sector. Here are these top biotech stocks to consider adding to your portfolio. Let’s
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...
In the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on.
Most readers would already know that Innoviva's (NASDAQ:INVA) stock increased by 2.5% over the past month. However, the...
Despite a decrease in net income, the company shows promise with the launch of new therapy and positive Phase 3 data
BURLINGAME, Calif., November 01, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the third quarter ended September 30, 2023, highlighted select corporate achievements and provided an overview of its key business initiatives.